CLINICAL_TRIALS
trial_result
· 2013-01-18
Clinical Trial Update: Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout [Phase 2]
Summary
This update covers a Phase 2 trial of pegylated recombinant uricase (PEG-uricase) for refractory gout, with results posted in 2013.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: John Sundy | Conditions: Gout | Phase 2 | Status: COMPLETED | Results posted: 2013-01-18